Ads
related to: fda approved intrathecal drugs for prostate cancer patients- Financial Assistance Info
Learn About Financial Support
Options for Eligible Patients.
- Real People, Real Stories
Visit Site to Watch Patient Videos
& Learn About Their Journey.
- Clinical Study Results
View Clinical Study Results
and Study Data Information.
- FAQs
Find Answers to Commonly
Asked Questions from Patients.
- Financial Assistance Info
Search results
Results from the WOW.Com Content Network
Gallium (68Ga) gozetotide was approved for medical use in the United States in December 2021, [13] [14] and in the European Union in December 2022. [10] It is the first drug approved by the US Food and Drug Administration (FDA) as a PET imaging agent. [12]
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer. [1] [2] It is used in the form padeliporfin di-potassium.[2]The most common side effects include problems with urinating (pain, inability to pass urine, strong urge to pass urine, frequent urination, and incontinence), sexual problems (erectile dysfunction and ejaculation failure), blood in ...
AstraZeneca Plc’s (AZN) and Merck Co.’s (MRK) Lynparza drug has received a green light from the U.S. Food and Drug Administration (FDA) for the treatment of patients with advanced prostate ...
Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC. [ 11 ] [ 12 ] [ 2 ] [ 13 ] [ 1 ] Shortly afterward, sipuleucel-T was added to the compendium of cancer treatments published by the National Comprehensive Cancer Network (NCCN) as a "category ...
The approval was based on data from a late-stage study, which showed that the subcutaneous form of the drug was not inferior to the intravenous formulation in patients with advanced kidney cancer ...
Ads
related to: fda approved intrathecal drugs for prostate cancer patients